Appili Therapeutics Inc Class A APLI
TSX · Canada · Health Technology
CAD 0.01000.00 (0.00%)
Market open· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Halifax, Nova Scotia--(Newsfile Corp. - September 29, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, announces that it has applied to voluntarily delist its Class A common shares (the "Common Shares") from the Toronto Stock Exchange (the "TSX") and transfer its listing to the NEX Board of the TSX Venture Exchange (the "NEX") as a result of the Company's failure to meet...
Appili adopts a new business strategy that focuses on the biodefence sectorHalifax, Nova Scotia--(Newsfile Corp. - August 14, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2027, which ended on June 30, 2026. All figures are in Canadian dollars unless
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 f
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.